跳至主要内容

Medicilon congratulates - Treatable and Accessible! Adult and adolescent Type A and Type B influenza! AnDiCon Bio's pill cures influenza with the new drug Madoxanavir - Phase III successful research

 On April 29th, AnDiCon Bio (AnDiCon) announced that the Phase III clinical trial of the new influenza drug Madoxanavir tablets (ADC189), which cures Type A and Type B influenza in adults and adolescents, has reached its primary endpoint, demonstrating excellent safety and efficacy."

Medicilon, as a partner of AnDiCon, provided formulation research services for the 'pediatric version' of the anti-influenza Class 1 Madoxanavir granules for influenza, assisting in its rapid advancement in preclinical research and development processes. This progress of Madoxanavir tablets not only validates its effectiveness and safety in treating influenza in adults and adolescents, but also indicates its enormous potential in the field of influenza treatment in children.

Andicon.webp

About AnDiCon Bio

The AnDiCon Bio Innovation Team, led by several academicians, focuses on the fields of respiratory anti-infection and pain.  The company has gathered a group of academic professionals and highly efficient and pragmatic senior talents at different stages of new drug development, including innovative drug design and synthesis, DMPK technology research and application, and research and development of high-end formulations suitable for special populations. AnDiCon Bio relies on the company's DMPK platform to establish a new drug R&D system based on metabolic differentiation. In addition to the anti-influenza new drug pipeline ADC189, the company's product pipeline also includes a variety of innovative drugs for respiratory pathogens, such as the anti-respiratory syncytial virus (RSV) drug ADC789 suspension, the novel anti-chlamydia super antibiotic ADC101 suspension, and innovative drugs like ADC308 tablets expected to fill the domestic gap in the treatment of endometriosis and uterine fibroids.  In 2022, the company completed a Pre-A round financing of RMB 100 million. In 2023, the company received strategic investment of tens of millions of RMB from Simcere Pharmaceutical (2096.HK). Since 2024, the company has completed a Series A financing of several hundred million RMB.  Looking forward, the company hopes to obtain more support and empowerment from investment institutions, accelerate the progress of innovative drug research and development, bring new treatment options to patients as soon as possible, and bring Chinese wisdom and solutions that are "healable" and accessible to China's public health security.

标签：
地点: 美国

评论

发表评论

此博客中的热门博文

In Vitro Enzyme Activity Assay

  Kinases play extensive and important roles in signal transduction and co-ordination of complex functions. Currently, about 300 kinase inhibitors have been approved for marketing, among which receptor tyrosine kinase (RTK) inhibitors are the main ones. Medicilon provides high-quality kinase profile screening and has one-stop kinase research services from assay development, high-throughput screening to selectivity analysis. In addition, Medicilon provides many other enzyme activity screens. Wide Variety Provides 200+  in vitro  enzymatic detection methods; 100+ kinases, including CTK, RTK, AGC, CMGC and other kinase families as well as important common mutations Project Flexibility Various types of plates for screening, such as 96 and 384; Multiple flexible kinase profiles, including TK kinase family, CDK kinase family, etc., to meet different customer customization needs. Various Methods Fluorescence detection; Chemiluminescence detection; Absorbance detection LanthaScr...
发表评论
阅读全文

Fluorescence Probes Synthesis

Medicilon's fluorescent probes and labeling platforms can provide fluorescent probe design and synthesis services for scientific institutions, drug R&D companies, and other customers. Design and synthesis steps Fluorescent probes are tools used to detect, measure and analyze biomolecules, cells and tissues. They achieve these purposes by emitting and receiving fluorescent signals. Medicilon can complete the design and synthesis of fluorescent probes for biomolecules. Selection of target molecules and determination of target. Selection of fluorescent dyes. Design of molecular structure. Synthesize probe molecules. Testing the properties of probe molecules. Custom synthesis Medicilon's fluorescent probes and labeling platforms can provide fluorescent probe design and synthesis services for scientific institutions, drug R&D companies, and other customers. After years of development, Medicilon's fluorescent probes and labeling platforms have accumulated rich experience...
发表评论
阅读全文

Custom Synthesis

Medicilon has synthesized over 10,000 individual compounds from gram to kilogram quantities, and many compounds are synthesized with more than ten synthetic steps. The overall synthesis success rate is over 95%. High quality products from mg to kg scale Reagents, intermediates, building blocks, and scaffolds Preparation of API or reference standards Development of synthetic routes for impurities and metabolites   On-site analytical support Product delivered with COA Medicilon offers integrated drug discovery services -- Chemistry, Biology & Preclinical Services
发表评论
阅读全文